Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Journal of the American College of Cardiology
|
December 4, 2020
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Massar Omar, Jesper Jensen, Peter H Frederiksen, et al.
Trials
|
June 23, 2019
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
ESC Heart Failure
|
February 19, 2026
Effects of Empagliflozin on Right Ventricular Free-Wall Strain in Patients with Heart Failure and Reduced Ejection Fraction
Massar Omar, Jesper Jensen, Mulham Ali, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 12, 2025
Effects of Empagliflozin on Right Ventricular Function in Heart Failure with Reduced Ejection Fraction
Massar Omar, Jesper Jensen, Peter H Frederiksen, et al.
American Heart Journal
|
March 9, 2026
Empagliflozin and Functional Aerobic Capacity in Individuals with Increased Risk of Heart Failure: The Empire Prevent Cardiac Trial
Julie H Larsen, Camilla F Andersen, Mathilde Mb Jessen, et al.
Journal of Cardiac Failure
|
March 14, 2026
The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial
Julie Hempel Larsen, Camilla Fuchs Andersen, Maria Callesen Hansen, et al.
European Journal of Preventive Cardiology
|
January 8, 2026
Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic Trial
Camilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
American Heart Journal
|
May 5, 2022
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial
Jesper Jensen, Massar Omar, Mulham Ali, et al.
Cardiovascular Diabetology
|
June 13, 2026
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial
Camilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
The Lancet. Diabetes & Endocrinology
|
December 28, 2020
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Journal of the American College of Cardiology
|
December 4, 2020
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Massar Omar, Jesper Jensen, Peter H Frederiksen, et al.
Trials
|
June 23, 2019
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
ESC Heart Failure
|
February 19, 2026
Effects of Empagliflozin on Right Ventricular Free-Wall Strain in Patients with Heart Failure and Reduced Ejection Fraction
Massar Omar, Jesper Jensen, Mulham Ali, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 12, 2025
Effects of Empagliflozin on Right Ventricular Function in Heart Failure with Reduced Ejection Fraction
Massar Omar, Jesper Jensen, Peter H Frederiksen, et al.
American Heart Journal
|
March 9, 2026
Empagliflozin and Functional Aerobic Capacity in Individuals with Increased Risk of Heart Failure: The Empire Prevent Cardiac Trial
Julie H Larsen, Camilla F Andersen, Mathilde Mb Jessen, et al.
Journal of Cardiac Failure
|
March 14, 2026
The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial
Julie Hempel Larsen, Camilla Fuchs Andersen, Maria Callesen Hansen, et al.
European Journal of Preventive Cardiology
|
January 8, 2026
Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic Trial
Camilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
American Heart Journal
|
May 5, 2022
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial
Jesper Jensen, Massar Omar, Mulham Ali, et al.
Cardiovascular Diabetology
|
June 13, 2026
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial
Camilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
The Lancet. Diabetes & Endocrinology
|
December 28, 2020
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
Page
of 5